利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.055 秒)

    Pharmaceutical compositions for treatment of MicroRNA related diseases
    3.
    发明授权
    Pharmaceutical compositions for treatment of MicroRNA related diseases 有权
    用于治疗微小RNA相关疾病的药物组合物

    公开(公告)号：US08404659B2

    公开(公告)日：2013-03-26

    申请号：US12921339

    申请日：2009-03-09

    申请人： Sakari Kauppinen ,  Niels Abrahamsen ,  Elisabeth S. Hildebrandt-Eriksen ,  Martin Munk

    发明人： Sakari Kauppinen ,  Niels Abrahamsen ,  Elisabeth S. Hildebrandt-Eriksen ,  Martin Munk

    IPC分类号： C12N15/11

    CPC分类号： C12N15/113 ,  C12N2310/141

    摘要： The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the present invention relate to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval.

    摘要翻译： 本发明提供治疗对下调微小RNA，mRNA，非编码RNA或病毒基因组的功能的药物敏感的疾病的组合物和方法。 特别地，已经发现，当给予灵长类动物时，可以获得抗微小RNA寡核苷酸的非常长的效果。 因此，本发明涉及用于治疗灵长类动物的药物组合物和方法，包括人，其中组合物以长时间间隔施用。

    Pharmaceutical compositions for treatment of microRNA related diseases
    5.
    发明申请
    Pharmaceutical compositions for treatment of microRNA related diseases 有权
    用于治疗微小RNA相关疾病的药物组合物

    公开(公告)号：US20090298916A1

    公开(公告)日：2009-12-03

    申请号：US12400625

    申请日：2009-03-09

    申请人： Sakari Kauppinen ,  Niels Abrahamsen ,  Elisabeth Hildebrandt-Eriksen ,  Martin Munk

    发明人： Sakari Kauppinen ,  Niels Abrahamsen ,  Elisabeth Hildebrandt-Eriksen ,  Martin Munk

    IPC分类号： A61K31/7088

    CPC分类号： C12N15/113 ,  C12N2310/141

    摘要： The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the present invention relate to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval.

    摘要翻译： 本发明提供治疗对下调微小RNA，mRNA，非编码RNA或病毒基因组的功能的药物敏感的疾病的组合物和方法。 特别地，已经发现，当给予灵长类动物时，可以获得抗微小RNA寡核苷酸的非常长的效果。 因此，本发明涉及用于治疗灵长类动物的药物组合物和方法，包括人，其中组合物以长时间间隔施用。

    Antisense oligonucleotides for inhibition of microRNA-21
    7.
    发明授权
    Antisense oligonucleotides for inhibition of microRNA-21 有权
    用于抑制microRNA-21的反义寡核苷酸

    公开(公告)号：US08729250B2

    公开(公告)日：2014-05-20

    申请号：US13415685

    申请日：2012-03-08

    申请人： Joacim Elmén ,  Phil Kearney ,  Sakari Kauppinen

    发明人： Joacim Elmén ,  Phil Kearney ,  Sakari Kauppinen

    IPC分类号： C07H21/04 ,  C12N15/11

    CPC分类号： C12N15/113 ,  C12N2310/113 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3515 ,  C12N2310/3521 ,  C12N2310/3533

    摘要： The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.

    摘要翻译： 本发明提供包含长度为8至26个核碱基的短单链寡核苷酸的药物组合物，其与选自miR19b，miR21，miR122a，miR155和miR375的人微小RNA互补。 短的寡核苷酸在减轻体内抑制miRNA方面特别有效。 发现将高亲和力核苷酸类似物并入寡核苷酸导致高度有效的抗微小RNA分子，其似乎通过与miRNA靶标形成几乎不可逆的双链体起作用，而不是基于RNA切割的机制，例如与 RNaseH或RISC。